| Literature DB >> 35639211 |
Tom Behrendt1, Robert Bielitzki2, Martin Behrens2,3, Fabian Herold4, Lutz Schega2.
Abstract
BACKGROUND: Intermittent hypoxia applied at rest or in combination with exercise promotes multiple beneficial adaptations with regard to performance and health in humans. It was hypothesized that replacing normoxia by moderate hyperoxia can increase the adaptive response to the intermittent hypoxic stimulus.Entities:
Keywords: Cardiovascular disease; Cognitive impairment; Geriatrics; Hypoxic conditioning; Metabolic disease; Therapy
Year: 2022 PMID: 35639211 PMCID: PMC9156652 DOI: 10.1186/s40798-022-00450-x
Source DB: PubMed Journal: Sports Med Open ISSN: 2198-9761
Fig. 1Graphical panorama of different “live low-train high” methods (modified from Girard et al. [2]). Please note that in the current literature the term “intermittent hypoxic–hyperoxic training” (IHHT) is commonly used for both passive and active applications. To avoid terminological ambiguity with respect to the term intermittent hypoxic–hyperoxic periods, we recommend to use the term "intermittent hypoxic–hyperoxic training" for active and “intermittent hypoxic–hyperoxic exposure” for passive applications
Fig. 2Flow chart of study selection. Please note that the term “inappropriate” refers to the inclusion and exclusion criteria used in this systematic review
Results of risk of bias assessment using the modified checklist by Downs and Black [76]
| References | Reporting | External validity | Internal validity | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | |
| Bayer et al. [ | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 |
| Glazachev et al. [ | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 0 |
| Susta et al. [ | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 |
| Dudnik et al. [ | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 0 |
| Glazachev et al. [ | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 1 |
| Serebrovska et al. [ | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 |
| Serebrovska et al. [ | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 |
| Bestavashvili et al. [ | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 |
Summary of study designs, participants’ characteristics, and characteristics of the interventions of the reviewed studies
| References | Design | Participants | Training characteristics | Characteristics of IHHE |
|---|---|---|---|---|
(1) Study design (2) Comparison groups | (1) Participants’ characteristics (2) Number of participants (f/m) (3) Mean age ± SD in years (4) Mean height ± SD in cm/mean weight ± SD in kg/mean BMI ± SD in kg/m2 | (1) Type and description of exercise (2) Single session duration (3) Training duration (4) Training frequency (5) Training density (6) Training setting | (1) Intensity of hypoxia/hyperoxia (FiO2) (2) Intra-session frequency (number of cycles) (3) Intra-session density (Duration of a single hypoxic/hyperoxic period) (4) Total time of IHHE procedure (5) Participants’ mean SpO2 at IHHE (hypoxic condition) (6) Intervention duration (7) Inter-session frequency of IHHE sessions (8) Inter-session density of IHHE sessions (9) Number of total sessions across the intervention duration | |
| Bayer et al. [ | (1) Randomized controlled trial (2) 2 groups [1] IHHE (normobaric IHHE and individual multimodal rehabilitation training) [2] Sham IHHE (simulated IHHE (normobaric normoxic air) and individual multimodal rehabilitation training) | (1) Geriatric patients (2) IHHE: 18 (13/5) Sham IHHE: 16 (14/2) (3) IHHE: 80.9 ± 7.8 Sham IHHE: 83.4 ± 5.5 (4) IHHE: 163.7 ± 8.3/72.0 ± 9.3/27.0 ± 3.9 Sham IHHE: 163.2 ± 8.5/66.8 ± 12.3/25.0 ± 6.6 | (1) Individual multimodal traininga (2) N.R. (3) 5–6 weeks (4) 2–3 sessions/week (16–20 sessions) (5) N.R. (6) 30 min physiotherapy (balance training, coordination training, and exercises to stimulate energy metabolism), 60 min occupational therapy (motor functional training, perceptual training, mental training, and cognitive training), and 20 min cycling | (1) 0.12/0.35 (2) N.R. (3) 4–6 min/1–2 min (4) 35–45 min (5) N.R. (6) 5–6 weeks (7) 2–3 sessions/week (8) N.R. (9) 14–15 sessions |
| Glazachev et al. [ | (1) Controlled trial (2) 2 groups [1] IHHE (normobaric IHHE) [2] Sham IHHE (patients were enrolled after completing a standard cardiac rehabilitation program (8 weeks, 2 days/week), simulated IHHE (normobaric normoxic air)) | (1) Patients with coronary arterial disease (NYHA functional class II and III) (2) IHHE: 27 (18/9) Sham IHHE: 19 (10/9) (3) IHHE: 63.9 ± 13.9 Sham IHHE: 79.1 ± 12.5 (4) IHHE: N.R./81.6 ± 13.9/N.R. Sham IHHE: N.R./79.1 ± 12.5/N.R. | (1) N.A. (2) N.A. (3) N.A. (4) N.A. (5) N.A. (6) N.A. | (1) 0.10–0.12/0.30–0.35 (2) 5–7 cycles (3) 4–6 min/3 min (4) N.R. (5) N.R. (6) 5 weeks (7) 3 sessions/week (8) N.R. (9) 15 sessions |
| Susta et al. [ | (1) Pilot study (2) 2 groups [1] IHHE (normobaric IHHE and low-intensity running performed by athletes with overtraining syndrome) [2] Control group (healthy athletes performing training as usual) | (1) Young track and field athletes with and without overtraining syndrome (2) IHHE: 15 (8/7) CG: 19 (12/7) (3) Overall: 18–20 (4) Overall: 176.4 ± 14.6/71.4 ± 6.9/N.R. | (1) 2 bouts of 30 min running at 40% VO2max with 10 min resta (2) 70 min (3) 4 weeks (4) 3 days/week (5) N.R. (6) Low-intensity running | (1) 0.11/0.30 (2) 6–8 cycles (3) 5–7 min/2–6 min (4) 40–50 min (5) N.R. (6) 4 weeks (7) 3 sessions/week (8) N.R. (9) 12 sessions |
| Dudnik et al. [ | (1) Randomized controlled trial (2) 2 groups [1] IHHE (normobaric IHHE) [2] Sham IHHE (simulated IHHE (normobaric normoxic air) and exercise program) | (1) Cardiology outpatients (2) IHHE: 15 (N.R.) Sham IHHE: 14 (N.R.) (3) IHHE: 66.7 ± 5.7 Sham IHHE: 65.0 ± 6.2 (4) IHHE: N.R./N.R./27.7 ± 2.3 Sham IHHE: N.R./N.R./28.9 ± 2.0 | (1) Standard tailored cardiopulmonary exercise program according to the European Society of Cardiologyb (2) N.R. (3) 8 weeks (4) 150 min/week (5) N.R. (6) 12–13 at Borg scale and/or 64–75% of maximal heart rate | (1) 0.11–0.12/0.30–0.33 (2) 5–7 cycles (3) 4–6 min/3 min (4) N.R. (5) |
| Glazachev et al. [ | (1) Randomized controlled trial (2) 2 groups [1] IHHE (normobaric IHHE) [2] Sham IHHE (simulated IHHE (normobaric normoxic air)) | (1) Patients with chronic coronary artery disease and angina pectoris of functional class II–III (2) Overall: 36 (26/10) IHHE: 17 (N.R.) Sham IHHE: 19 (N.R.) (3) Overall: 68.2 ± 6.1 (4) N.R./N.R./N.R. | (1) N.A. (2) N.A. (3) N.A. (4) N.A. (5) N.A. (6) N.A. | (1) 0.11–0.12/0.35 (2) N.R. (3) 2–6 min/1–2 min (4) 45–50 min (5) N.R. (6) 3 weeks (7) 5 sessions/week (8) 1 session per day for 5 days and 2 days rest (e.g. Monday to Friday: training, Saturday and Sunday: rest) (9) 15 sessions |
| Serebrovska et al. [ | (1) Randomized controlled trial (2) 3 groups [1] IHHE (normobaric IHHE) [2] IHE (normobaric intermittent hypoxic exposure) [3] Sham IHHE (simulated IHHE (normobaric normoxic air)) | (1) Patients with prediabetes (2) IHHE: 17 (13/4) IHE: 22 (15/7) Sham IHHE: 16 (10/6) (3) IHHE: 67.7 ± 7.7 IHE: 64.2 ± 6.6 Sham IHHE: 67.5 ± 8.7 (4) IHHE: 163 ± 6.0/84.9 ± 12.8/32.2 ± 4.6 IHE: 164 ± 9.5/86.3 ± 14.2/32.5 ± 6.7 Sham IHHE: 163 ± 6.0/84.9 ± 12.8/32.2 ± 4.6 | (1) Intermittent hypoxic exposureb (2) N.R. (3) 3 weeks (4) 5 sessions/week (15 sessions) (5) N.R. (6) Intermittent hypoxic exposure (5 min of hypoxia (12% FiO2) and 5 min of normoxia (~ 21% FiO2)) | (1) 0.12/0.33 (2) 4 cycles (3) 5 min/3 min (4) N.R. (5) N.R. (lowest: ~ 79%) (6) 3 weeks (7) 5 sessions/week (8) N.R. (9) 15 sessions |
| Serebrovska et al. [ | (1) Pilot study (2) 3 groups [1] IHHE (patients with mild cognitive impairments performing normobaric IHHE) [2] Sham IHHE (patients with mild cognitive impairments performing simulated IHHE (normobaric normoxic air)) [3] Control group (healthy participants performing either IHHE nor Sham IHHE) | (1) Patients with mild cognitive impairments (2) IHHE: 8 (6/7) Sham IHHE: 6 (6/0) Control group: 7 (6/1) (3) IHHE: 68.2 ± 7.2 Sham IHHE: 72.6 ± 6.9 Control group: 63.0 ± 10.0 (4) IHHE: N.R./N.R./27.7 ± 2.0 Sham IHHE: N.R./N.R./26.3 ± 5.5 Control group: N.R./N.R./26.5 ± 3.6 | (1) N.A. (2) N.A. (3) N.A. (4) N.A. (5) N.A. (6) N.A. | (1) 0.12/0.33 (2) 4 cycles (3) 5 min/3 min (4) N.R. (5) N.R. (6) 3 weeks (7) 5 sessions/week (8) N.R. (9) 15 sessions |
| Bestavashvili et al. [ | (1) Randomized controlled trial (2) 2 groups [1] IHHE (normobaric IHHE) [2] Sham IHHE (simulated IHHE (normobaric normoxic air)) | (1) Patients with metabolic syndrome (2) IHHE: 32 (18/14) Sham IHHE 33 (14/19) (3) IHHE: 60.0 (45.5; 65.5) Sham IHHE: 61.5 (56.2; 66.0) (4) IHHE: N.R./92.0 (81.0; 114.0)/34.3 (30.2; 38.0) Sham IHHE: N.R./92.5 (82.8; 104.0)/32.4 (30.8; 35.8) | (1) N.A. (2) N.A. (3) N.A. (4) N.A. (5) N.A. (6) N.A. | (1) 0.11–0.12/0.30–0.35 (2) N.R. (3) 4–7 min/2–4 min (4) 40–45 min (5) N.R. (6) 3 weeks (7) 5 sessions/week (8) One session per day for 5 days and 2 days rest (e.g. Monday to Friday: training, Saturday and Sunday: rest) (9) 15 sessions |
BMI body mass index, CAD coronary artery disease, CG control group, f female, FO fraction of inspired oxygen, IHE intermittent hypoxic exposure, IHHE intermittent hypoxia–hyperoxia exposure, m male, N.A. not available, N.R. not reported, NYHA New York Heart Association, RIP remote ischaemic preconditioning, SD standard deviation, SO blood oxygen saturation measured with finger pulse oximeter
aDescribes the characteristics of an additional training that is carried out in addition to the IHHE
bDescribes the characteristics of the training that is performed by an control group
Summary of assessed outcomes and main results of the reviewed studies
| References | Assessed outcomes | Main results |
|---|---|---|
| Bayer et al. [ | Dementia detection test (DemTect) Clock drawing test (CDT) Six-minute Walk Test (6MWT) Resting heart rate Resting systolic and diastolic blood pressure Resting oxygen saturation | ↑ DemTect in IHHE (11.2 ± 3.5 points vs. 14.2 ± 3.7 points) ↑ CDT in IHHE (7.8 ± 2.9 points vs. 8.4 ± 3.0 points) ↑ 6MWT in IHHE and sham IHHE (234.3 ± 94.7 m vs. 290.7 ± 83.1 m; 250.6 ± 94.3 m vs. 277.7 ± 96.3 m) ↑ DemTect in IHHE compared to sham IHHE (post-test: 14.2 ± 3.7 points vs. 11.3 ± 3.6 points) ↑ CDT in IHHE compared to sham IHHE (post-test: 8.4 ± 3.0 points vs. 6.8 ± 2.6 points) ↑ 6MWT in IHHE compared to sham IHHE (post-test: 290.7 ± 83.1 m vs. 277.7 ± 96.3 m) |
| Glazachev et al. [ | Cardiopulmonary exercise test Resting heart rate Resting systolic and diastolic blood pressure Resting left ventricular ejection fraction Haemoglobin concentration, reticulocytes, total cholesterol, high- and low-density lipoprotein, and glucose Atherogenic index ((total cholesterol − high-density lipoprotein) ÷ high-density lipoprotein) Seattle Angina Questionnaire (SAQ) | ↓ Angina as a reason to stop cardiopulmonary exercise test in IHHE (12 vs. 6 vs. 3b, c) ↑ Time to exhaustion in cardiopulmonary exercise test (modified Bruce protocol) in IHHE (354 ± 194 s vs. 383 ± 141 s vs. 395 ± 130 sb) ↑ Time to exhaustion in cardiopulmonary exercise (Bruce protocol) in IHHE (280 ± 126 s vs. 295 ± 79 s vs. 332 ± 113 sb) ↑ VO2peak in IHHE (14.3 ± 4.2 ml-O2/min/kg vs. 16.1 ± 4.2 ml-O2/min/kga vs. 15.4 ± 4.5 ml-O2/min/kga) ↓ Systolic blood pressure in IHHE (151 ± 19 mmHg vs. 130 ± 13 mmHga vs. 129 ± 11 mmHgb) ↓ Diastolic blood pressure in IHHE (85 ± 11 mmHg vs. 73 ± 7 mmHga vs. 75 ± 9 mmHgb) ↓ Resting heart rate in IHHE (71.5 ± 11.4 beats/min vs. 67.7 ± 8.3 beats/mina vs. 66.6 ± 10.0 beats/minb) ↓ Maximum heart rate in IHHE (122 ± 19 beats/min vs. 120 ± 14 beats/mina vs. 116 ± 14 beats/minb) ↑ Left ventricle ejection fraction in IHHE (14.3 ± 4.2% vs. 16.1 ± 4.2%a vs. 15.4 ± 4.5%b) ↑ Reticulocytes in IHHE (9.0 ± 4.5% vs. 11.3 ± 6.2%a vs. 9.2 ± 4.8%b) ↓ Total cholesterol in IHHE (5.6 ± 1.4 mmol/L vs. 5.1 ± 1.2 mmol/La vs. 5.5 ± 1.4 mmol/Lb) ↓ Low-density lipoprotein in IHHE (3.5 ± 1.2 mmol/L vs. 3.2 ± .9 mmol/La vs. 2.6 ± 1.3 mmol/Lb, c) ↓ Atherogenic index in IHHE (4.7 ± 1.8 vs. 3.4 ± 1.3a vs. 3.5 ± 1.5c) ↓ Glucose in IHHE (7.1 ± 2.3 mmol/L vs. 6.5 ± 1.7 mmol/L vs. 6.2 ± 1.7 mmol/Lc) ↑ SAQ physical limitation subscale in IHHE (43.3 ± 17.7 vs. 51.6 ± 13.1a vs. 53.7 ± 17.8b) ↑ SAQ angina stability subscale in IHHE (56.5 ± 27.4 vs. 78.3 ± 23.3a vs. 79.6 ± 22.7b) ↑ SAQ angina frequency subscale in IHHE (59.6 ± 27.6 vs. 81.1 ± 17.9a vs.80.9 ± 18.2b) ↑ SAQ treatment satisfaction subscale in IHHE (60.7 ± 16.2 vs. 77.4 ± 16.8a vs. 80.5 ± 17.7b) ↑ SAQ disease perception subscale in IHHE (47.2 ± 18.9 vs. 60.8 ± 17.8 vs. 63.4 ± 17.4b) ↓ Angina as a reason to stop cardiopulmonary exercise test in IHHE compared to sham IHHE (1-month follow-up: 3 vs. 6) ↑ Exercise time (modified Bruce protocol) in IHHE compared to sham IHHE (post-test: 383 ± 141 s vs. 280 ± 92) ↑ VO2peak in IHHE compared to sham IHHE (1-month follow-up: 15.4 ± 4.5 ml-O2/min/kg vs. 17.8 ± 4.9 ml-O2/min/kg) ↑ Reticulocytes in IHHE compared to sham IHHE (post-test: 11.3 ± 6.2% vs. 6.4 ± 3.6%; 1-month follow-up: 9.2 ± 4.8% vs. 5.11 ± 3.13%) ↓ Total cholesterol in IHHE compared to sham IHHE (post-test 5.1 ± 1.2 mmol/L vs. 5.5 ± 0.9 mmol/L) ↓ Low-density lipoprotein in IHHE compared to sham IHHE (post-test: 3.2 ± .9 mmol/L vs. 3.6 ± 0.8 mmol/L; 1-month follow-up: 2.6 ± 1.3 mmol/L vs. 3.5 ± 0.8 mmol/L) ↓ Atherogenic index in IHHE compared to sham IHHE (post-test: 3.4 ± 1.3 vs. 3.6 ± 1.1) ↑ Atherogenic index in IHHE compared to sham IHHE (1-month follow-up: 3.5 ± 1.5 vs. 3.4 ± 1.0) |
| Susta et al. [ | Cardiopulmonary exercise test Inotropic reserve index (IRI, (maximal systolic blood pressure − resting systolic blood pressure) ÷ resting systolic blood pressure) Chronotropic reserve index (CRI, (maximal heart rate − resting heart rate) ÷ resting heart rate) Resting heart rate and heart rate variability Inotropic reserve index (IRI, (maximal systolic blood pressure − resting systolic blood pressure) ÷ resting systolic blood pressure) Chronotropic reserve index (CRI, (maximal heart rate − resting heart rate) ÷ resting heart rate) Resting heart rate and heart rate variability Red blood cell count, reticulocyte, haemoglobin concentration, and haematocrit Oxygen saturation (SpO2) Maximal heart rate (HRmax) | ↑ PWC170 in IHHE (170.8 ± 44.8 W vs. 191.9 ± 26.9 W) ↓ IRI in IHHE (65.8 ± 3.6% vs. 54.8 ± 5.4%) ↓ CRI in IHHE (50.0 ± 5.3% vs. 38.0 ± 5.9%) ↑ SpO2 during hypoxic test in IHHE (77.9 ± 6.8% vs. 84.2 ± 5.7%) ↓ HRmax during hypoxic test in IHHE (82.2 ± 14.6 beats/min vs. 76.6 ± 11.0 beats/min) ↑ Standard deviation of R–R intervals in IHHE (54.0 ± 24.7 ms vs. 76.0.2 ± 26.8 ms) ↓ Low frequency power in IHHE (1300 ± 661 ms2 vs. 801 ± 673 ms2) ↑ High frequency power in IHHE (277 ± 188 ms2 vs. 624 ± 468 ms2) ↓ Low frequency to high frequency index in IHHE (8.01 ± 7.51 vs. 1.45 ± 1.71) ↓ PWC170 in IHHE compared to control group (pre-test: 170.8 ± 44.8 W vs. 204.2 ± 13.8 W; post-test: 191.9 ± 26.9 W vs. 278.0 ± 19.3 W) ↑ IRI in IHHE compared to control group (pre-test: 65.8 ± 3.6% vs. 50.8 4.1%; post-test: 54.8 ± 5.4% vs. 49.6 3.8%) ↑ CRI in IHHE compared to control group (pre-test: 50.0 ± 5.3% vs. 37.5 ± 4.9%) ↓ SpO2 during hypoxic test in IHHE compared to control group (pre-test: 77.9 ± 6.8% vs. 83.7 ± 9.0%) ↑ HRmax during hypoxic test in IHHE compared to control group (pre-test: 82.2 ± 14.6 beats/min vs. 79.7 ± 13.1 beats/min) ↓ R–R intervals in IHHE compared to control group (post-test: 890 ± 160 ms vs. 990 ± 180 ms) ↓ Standard deviation of R–R intervals in IHHE (54.0 ± 24.7 ms vs. 82.0 ± 24.8 ms) ↑ HRrest in IHHE compared to control group (post-test: 67.1 ± 13.7 beats/min vs. 60.4 ± 4.6 beats/min) ↓ High frequency in IHHE compared to control group (pre-test: 277 ± 188 ms vs. 1100 ± 344 ms2; post-test: 624 ± 468 ms2 vs. 1167 ± 501 ms2) ↑ Low frequency to high frequency index in IHHE compared to control group (pre-test: 8.01 ± 7.51 vs. 2.2 ± 1.0) |
| Dudnik et al. [ | Cardiopulmonary exercise test Resting heart rate Resting systolic and diastolic blood pressure Red blood cells count, white blood cell count, platelets, haemoglobin concentration, reticulocytes | ↑ VO2peak in IHHE (13.9 ± 2.5 ml-O2/min/kg vs. 19.9 ± 6.1 ml-O2/min/kg) ↑ Reticulocytes in IHHE compared to sham IHHE (post-test: 1.1 ± 0.5% vs. 0.6 ± 0.3%) ↓ Diastolic blood pressure in IHHE compared to sham IHHE (pre-test: 82.1 ± 11.1 mmHg vs. 77.9 ± 9.7 mmHg; post-test: 74.7 ± 8.9 mmHg vs. 82.0 ± 9.3 mmHg) |
| Glazachev et al. [ | Cardiopulmonary exercise test Total cholesterol, high and low-density lipoprotein, triglycerides, and glucose Quality of life Medical Outcome Study 36-item Short Form Health Survey (MOS SF-36) Seattle Angina Questionnaire (SAQ) | ↑ Time to exhaustion in cardiopulmonary exercise test (modified Bruce protocol) in IHHE (303 ± 147 s vs. 362 ± 124 sa vs. 342 ± 113 s) ↑ Metabolic equivalent in IHHE (3.5 ± 1.2 vs. 39.1 ± 1.0 s vs. 4.2 ± 1.2 s) ↑ VO2 at anaerobic threshold in IHHE (11.5 ± 1.3 ml-O2/min/kg vs. 13.8 ± 2.0 ml-O2/min/kga vs. 13.8 ± 0.3 ml-O2/min/kgb) ↑ MOS SF-36 physical functioning subscale in IHHE (84.2 ± 13.0 vs. 55.7 ± 12.0a vs. 51.7 ± 14.0) ↑ MOS SF-36 role physical subscale in IHHE (47.0 ± 17.8 vs. 61.7 ± 18.8a vs. 55.8 ± 19.0) ↑ MOS SF-36 body pain subscale in IHHE (22.0 ± 39.4 vs. 48.5 ± 43.7 vs. 58.8 ± 39.0b) ↑ MOS SF-36 vitality subscale in IHHE ↑ MOS SF-36 physical functioning subscale in IHHE compared to sham IHHE (post-test: 61.7 ± 18.8 vs. 47.5 ± 11.9) ↑ MOS SF-36 body pain subscale in IHHE compared to sham IHHE (post-test: 48.5 ± 43.7 vs. 27.3 ± 8.9) ↑ metabolic equivalent in IHHE compared to sham IHHE (post-test: 3.5 ± 0.9 vs. 3.8 ± 1.0) ↑ VO2peak in IHHE compared to sham IHHE (post-test: 16.9 ± 1.4 ml-O2/min/kg vs. 12.0 ± 6.3 ml-O2/min/kg) |
| Serebrovska et al. [ | Total cholesterol, high- and low-density lipoprotein, and triglycerides Fasting glucose level and 2 h post-oral glucose tolerance test glucose level Oxygen saturation (SpO2) Maximal heart rate (HRmax) | ↑ Minimum SpO2 during hypoxic test in IHHE (79.4 ± 3.8% vs. 81.5 ± 3.9a % vs N.R.b) ↓ Fasting glucose in IHHE and IHE (IHHE: 6.3 ± 0.5 mmol/L vs. 5.8 ± 0.7 mmol/La vs. 5.3 ± 0.8 mmol/Lb; IHE: 6.5 ± 0.4 mmol/L vs. 5.4 ± 0.5 mmol/La vs. 5.1 ± 0.6 mmol/Lb) ↓ 2-h post-oral glucose tolerance test glucose level in IHHE and IHE (IHHE: 7.9 ± 0.9 mmol/L vs. 6.8 ± 1.0 mmol/La vs. 6.4 ± 1.3 mmol/Lb; IHE: 8.3 ± 1.0 mmol/L vs. 7.0 ± 1.9 mmol/La vs. 6.4 ± 1.1 mmol/Lb) ↓ Total cholesterol in IHHE and IHE (IHHE: 6.3 ± 1.1 mmol/L vs. 5.7 ± 1.0 mmol/La vs. 6.1 ± 1.3 mmol/L; IHE: 6.2 ± 1.2 mmol/L vs. 5.3 ± 0.9 mmol/La vs. 5.8 ± 1.2 mmol/L) ↓ Low-density lipoprotein cholesteral in IHHE and IHE (IHHE: 4.2 ± 1.3 mmol/L vs. 3.5 ± 1.0 mmol/La vs. 3.5 ± 1.3 mmol/Lb; IHE: 4.0 ± 1.3 mmol/L vs. 3.3 ± 1.0 mmol/La vs. 3.4 ± 1.0 mmol/L) ↓ Fasting glucose in IHHE compared to sham IHHE (1-month follow-up: 5.3 ± 0.8 mmol/L; vs 6.1 ± 0.8 mmol/L) ↓ Fasting glucose in IHE compared to sham IHHE (post-test: 5.4 ± 0.5 mmol/L vs. 6.12 ± 0.8 mmol/L; 1-month follow-up: 5.1 ± 0.6 mmol/L vs. 6.1 ± 0.8 mmol/L) ↓ 2-h post-oral glucose tolerance test glucose level in IHHE compared to sham IHHE (post-test: 6.8 ± 1.0 mmol/L vs. 8.3 ± 1.1 mmol/L; 1-month follow-up: 6.4 ± 1.3 mmol/L vs. 8.2 ± 1.2 mmol/L) ↓ 2-h post-oral glucose tolerance test glucose level in IHE compared to sham IHHE (post-test: 7.0 ± 1.9 mmol/L vs. 8.3 ± 1.1 mmol/L; 1-month follow-up: 6.4 ± 1.1 mmol/L vs. 8.2 ± 1.2 mmol/L) ↓ Total cholesterol in IHE compared to sham IHHE (1-month follow-up: 5.3 ± 0.9 mmol/L vs. 6.2 ± 0.9 mmol/L) |
| Serebrovska et al. [ | Montreal Cognitive Assessment Test (MoCA) Long latency cognitive event-related potential (P300, N200) Amyloid-β and amyloid precursor protein (APP130, APP110, and APP110/APP130 ratio) Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) Stimulated neutrophil extracellular traps formation in peripheral blood (NETst) | ↑ MoCA test score in IHHE (19.6 ± 1.6% vs. 22.1 ± 1.7%a vs. 21.3 ± 1.6%) ↑ APP130 in IHHE (0.4 ± 0.1 r.U. vs. 0.7 ± 0.1 r.U.a vs. 0.6 ± 0.1 r.U.b) ↑ APP110 in IHHE (0.6 ± 0.1 r.U. vs. 0.7 ± 0.1 r.U.a vs. 0.8 ± 0.1 r.U.b) ↑ APP-ratio in IHHE (0.7 ± 0.1 vs. 0.9 ± 0.1a vs. 0.8 ± 0.1) ↓ Amyloid-β in IHHE (2.6 ± 0.3 r.U. vs. 2.2 ± 0.4 r.U.a vs. 2.1 ± 0.4 r.U.b) ↓ NETst in IHHE (12.7 ± 6.2% vs. 8.8 ± 3.3% vs. 6.1 ± 3.5%b) ↓ NETns in IHHE (9.5 ± 2.1% vs. 4.5 ± 1.1%a vs. 4.2 ± 1.3%b) ↓ BACE1 in IHHE (85.3 ± 55.6 r.U. vs. 36.8 ± 34.6 r.U.a vs. 45.6 ± 32.8 r.U.) ↑ APP130 in IHHE compared to sham IHHE (post-test: 0.7 ± 0.1 r.U. vs. 0.4 ± 0.1 r.U.; 1-month follow-up: 0.6 ± 0.1 r.U. vs. 0.4 ± 0.1 r.U.) ↑ APP110 in IHHE compared to sham IHHE (post-test: 0.7 ± 0.1 r.U. vs. 0.5 ± 0.1 r.U.; 1-month follow-up: 0.8 ± 0.1 r.U. vs. 0.5 ± 0.1 r.U.) ↑ APP-ratio in IHHE compared to sham IHHE (post-test: 0.9 ± 0.1 vs. 0.8 ± 0.1) ↑ Amyloid-β in IHHE compared to sham IHHE (post-test: 2.2 ± 0.4 r.U. vs. 2.8 ± 0.4 r.U.; 1-month follow-up: 2.1 ± 0.4 r.U. vs. 2.8 ± 0.2 r.U.) ↓ NETst in IHHE (1-month follow-up: 6.1 ± 3.5% vs. 11.2 ± 3.6%) ↓ NETns in IHHE (post-test: 4.5 ± 1.1% vs. 9.22 ± 3.9%; 1-month follow-up: 4.2 ± 1.3% vs. 8.25 ± 2.0%) ↓ BACE1 in IHHE (85.3 ± 55.6 r.U. vs. 36.8 ± 34.6 r.U.a vs. 45.6 ± 32.8 r.U.) |
| Bestavashvili et al. [ | Body mass index (BMI) Waist circumference Hip circumference Total cholesterol, high- and low-density lipoprotein, and triglycerides Alanine aminotransferase (ALT) Aspartate aminotransferase (AST) Galectin-3 Nitric oxide synthase 2 (NOS2) Heat shock proteins (Hsp70) Transforming growth factor beta-1 (TGF beta-1) Heart-type fatty acid binding protein (H-FABP) High-sensitive C-reactive protein (CRP-hs) | ↓ BMI in IHHE (34.2 ± 5.2 kg/m2 vs. 33.3 ± 5.2 kg/m2) ↓ Waist circumference in IHHE (116.2 ± 11.2 cm vs. 111.0 ± 10.6 cm) ↓ Hip circumference in IHHE (114.1 ± 9.4 cm vs. 110.3 ± 9.4 cm) ↑ Total cholesterol in sham IHHE (4.8 ± 1.2 mmol/L vs. 5.1 ± 1.1 mmol/L) ↓ ALT in IHHE (37.3 ± 26.1 u/L vs. 29.0 ± 15.3 u/L) ↓ HSP70 in IHHE (0.963 ± 0.316 ng/mL vs. 0.865 ± 0.334 ng/mL) ↓ CRP-hs in IHHE (3.608 ± 3.448 mg/L vs. 2.237 ± 1.527 mg/L) ↓ NTproBNP in IHHE (27.5 ± 45.1 pmol/L vs. 20.4 ± 34.2 pmol/L) ↓ ALT in IHHE compared to sham IHHE (post-test: 29.0 ± 15.3 u/L vs. 36.2 ± 21.5 u/L) ↓ NTproBNP in IHHE compared to sham IHHE (post-test: 20.4 ± 34.2 pmol/L vs. 34.9 ± 62.1 pmol/L) ↓ Δ-BMI in IHHE compared to sham IHHE (-0.9 ± 0.5 vs. 0.3 ± 0.6) ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ |
ALT Alanine aminotransferase, APP amyloid precursor protein, AST Aspartate aminotransferase, BACE1 beta-site amyloid precursor protein cleaving enzyme 1, BMI body mass index, CDT Clock-drawing Test, CRI chronotropic reserve index, CRP-hs High-sensitive C-reactive protein DemTect Dementia Detection Test, FO fraction of inspired oxygen, H-FABP Heart-type fatty acid binding protein, Hsp70 Heat shock proteins, HR maximum heart rate, HR resting heart rate, IRI inotropic reserve index, IHE intermittent hypoxic exposure, IHHE intermittent hypoxia–hyperoxia exposure, IQR interquartile range, MoCA Montreal-Cognitive-Assessment, MOS SF-36 Medical Outcome Study 36-item Short Form Health Survey, NET stimulated neutrophil extracellular traps formation, NET not stimulated neutrophil extracellular traps formation, NOS2 Nitric oxide synthase 2, N.R. not reported, NTproBNP N-terminal pro-hormone of brain natriuretic peptide, PWC130 physical work capacity at a heart rate of 130 beats min−1, r.U. relative units, SAQ Seattle Angina Questionnaire, TGF beta-1 Transforming growth factor beat-1, VO peak oxygen uptake, 6MWT Six-minute Walk Test
ap values < .05 for differences between pre-test and post-test (time effect)
bp values < .05 for differences between pre-test and 1-month follow-up (time effect)
cp values < .05 for differences between post-test and 1-month follow-up (time effect)
Overview of the general variables determining the hypoxic dose and preliminary synopsis for the application of intermittent hypoxic–hyperoxic exposure (IHHE) interventions
| Variable and description | IHHE protocola |
|---|---|
| Intensity of hypoxia | |
| Level of hypoxemia, typically reported as oxygen saturation of the blood (SpO2, internal intensity) or fraction of inspired oxygen (FiO2, external intensity) | FiO2 = 0.10–0.12 |
| Intensity of hyperoxia | |
| Fraction of inspired oxygen (FiO2, external intensity) during hyperoxic periods | FiO2 = 0.30–0.40 |
| Duration of a single hypoxic period | |
| Time spent in hypoxia before the onset of reoxygenation period (i.e. onset of normoxia or hyperoxia period) | 2–6 min |
| Intra-session frequency | |
| Number of hypoxic periods that are interspersed with hyperoxic or normoxic periods (cycle) within a single session or day | 4–8 cycles |
| Intra-session density | |
| Distribution of hypoxic periods across a distinct time interval with regard to reoxygenation time (i.e. duration of normoxia or hyperoxia period) within a single session or day | 1–4 min |
| Inter-session frequency | |
| The number of IHHE sessions across a distinct time interval | 3–5 sessions per week |
| Inter-session density | |
| Distribution of IHHE sessions across a distinct time interval with regard to recovery time in-between the IHHE sessions | Every second day until daily for 5 days interspersed with 2 days rest |
| Duration | |
| IHHE intervention duration | ≥ 3 weeks |
aPlease note that the displayed variables were frequently reported in the reviewed studies and can serve as starting point for future investigations. However, currently no specific recommendations concerning the dose being most suitable for a distinct population can be provided since there is not enough evidence in the literature allowing us to draw robust and reliable conclusions in this direction